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Univers
osting by E
cense.Abstract Different pyrazolone derivatives were prepared by microwave irradiation and ultrasound
assisted methods besides the traditional ones. They were used for synthesis of some derivatives of
spiropiperidine-4,40-pyrano[2,3-c]pyrazole, dihydropyrano[2,3-c]pyrazole, pyrazole-4-carbothioa-
mide, 4-(2-oxo-1,2-diphenylethylidene)-1H-pyrazol-5(4H)-one, azopyrazole, arylmethylenebis-1H-
pyrazol-5-ol and araylidene-1H-pyrazol-5(4H)-one via reactions with different reagents applying
the ultrasound method in some cases.
ª 2010 King Saud University. Open access under CC BY-NC-ND license.1. Introduction
In recent years, developing multicomponent reactions in order
to produce biologically active compounds has been accelerated
and thus became one of the very important areas of research in
organic and medicinal chemistry. Several heterocyclic com-
pounds containing pyrazolone moiety were found to be useful
intermediates for medical drugs (Huang et al., 1987), and fur-6 1 477 2245.
(F.E.M. El-Baih), hhazimi@
ity.
lsevierthermore have a wide range of approved biological and phar-
maceutical activities, such as analgesic and antipyretic
properties (Brogden, 1986; Costa et al., 2006), anti-ischemic ef-
fects (Watanabe et al., 1994; Kawai et al., 1997; Wu et al., 2002)
anti-inﬂammatory (Brogden, 1986.), antiviral (Sujatha et al.,
2009), antitumor (Park et al., 2005; Tripathy et al., 2006; Casas
et al., 2008), antibacterial (Liu et al., 2007; Bondock et al.,
2008) and other activities (Geronikaki et al., 2004; Abdel-Aziz
et al., 2009). Numerous pyrazolone derivatives are also used in
dye industry (Li et al., 2008; Metwally et al., 2008) and as anti-
corrosives (Abdallah, 2003; Fouda et al., 2006). In continuation
of our work on ﬁve membered ring heterocycles (El-Baih et al.,
2000, 2006a,b) and due to the above mentioned diverse proper-
ties of pyrazolones, we report herein the synthesis of some novel
pyrazolone derivatives using simple methodology, i.e. ultra-
sound method which in turn proved to be an efﬁcient and be-
nign multicomponent procedure. Furthermore, conventional
methods for the synthesis of the title compounds have also been
adopted for comparison purposes.
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2.1. General
Melting points were determined using an electrothermal’s
IA9000 series digital capillary melting point apparatus. IR
spectra were obtained as KBr discs on a 1000- Perkin Elmer
FT-IR spectrophotometer. 1H and 13C NMR spectra were re-
corded on a JEOL ECP-400 NMR in CDCl3 (or DMSO-d6)
using TMS as an internal standard. Chemical shifts are given
in d ppm and coupling constants (J) are given in Hz. The
assignments of all carbons are made by comparison to 13C
NMR spectra of structurally related compounds (Becher
et al., 1992; Brugnolotti et al.,1988; Holzer et al., 2004; Liu
et al., 2007) and theory ground (Lambert and Mazzola,
2004; Pavia et al., 2001). Electron impact (EI) MS spectra were
acquired with the aid of a Shimadzu GCMSQP5050A spec-
trometer, DB-1 glass column 30 m, 0.25 mm, ionization energy
70 eV, at the Chemistry Department, College of Science, King
Saud University. X-ray was recorded on single crystal Nonius
Kappa, CCD diffractometer with Oxford Cryosystems nitro-
gen gas low temperature cryostats at University of Bath, UK.
2.2. 1,3-Disubstituted-1H-pyrazol-5(4H)-one (2a–l)
2.2.1. Method A: for synthesis of 2a–h
They were prepared as reported (Vogel, 1966).
2.2.2. Method B: for synthesis of 2i–l
They were prepared as reported (Fitton and Smalley, 1968).
2.2.3. Method C: for synthesis of 2a–l
Hydrazine hydrate or any of the hydrazine derivatives
(0.01 mol) was added dropwise to the corresponding b-keto es-
ter (0.01 mol) contained in a 100 mL beaker, then covered with
a watch glass. The mixture was irradiated with microwave
(300 W) for 1–15 min. The cold reaction mixture was treated
with ethanol, ether or pet. ether (60–80 C). The solid product
was ﬁltered, dried and recrystallized (in some cases the solid
obtained was pure and did not need recrystallization).
2.2.4. Method D: for synthesis of 2a–k
A solution of hydrazine hydrate or any of the hydrazine deriv-
atives (0.01 mol) in ethanol (0.8 mL) was added dropwise to
the corresponding b-keto ester (0.01 mol) contained in a
25 mL conical ﬂask. The mixture was irradiated in the water
bath of an ultrasonic cleaner for 2–25 min. The cold reaction
mixture was treated with ethanol, ether, or pet. ether (60–
80 C). The solid product was ﬁltered and dried. The solid ob-
tained was pure and did not need recrystallization.
2.3. 2,5-Dimethyl-1H-pyrazol-3(2H)-one (2aa)
Pale orange powder, m.p. 116–117 C (from benzene); Yield
70%A, 62%C, 76%D; IR (cm1): 2448–2927 (OH); 1H NMR
(DMSO-d6): 1.99 (3H, s, CH3 at position 3), 3.37 (3H, s,
CH3 at position 1), 5.10 (1H, s, H-4), 10.84 (br.s, NH);
13C
NMR: 14.4 (CH3 at position 3), 32.7 (CH3 at position 1),
86.9 (C-4), 145.8 (C-3), 172.8 (C‚O); MS: m/z (%) 112
(100) [M+] (C5H8N2O), 113 (23) [M+1], 83 (3) [MCOH],
70 (11) [MC2H2O], 69 (46) [70AH], 54 (12) [83AN2H].2.4. 1,3-Dimethyl-1H-pyrazol-5(4H)-one (2ab)
Pale orange powder, m.p. 116–117 C (from benzene); Yield
70%A, 62%C, 76%D; IR (cm1): 2448-2927 (OH); 1H NMR
(CDCl3): 2.04 (3H, s, CH3 at position 3), 3.13 (2H, s, CH2),
3.21 (3H, s, CH3 at position 1);
13C NMR: 16.9 (CH3 at posi-
tion 3), 31.1 (CH3 at position 1), 41.5 (C-4), 155.6 (C-3), 172.3
(C‚O); MS: m/z (%) 112 (100) [M+] (C5H8N2O), 113 (23)
[M+1], 83 (3) [MCOH], 70 (11) [MC2H2O], 69 (46)
[70AH], 54 (12) [83AN2H].
2.5. 1,3-Diphenyl-1H-pyrazol-5(4H)-one (2bb)
Pale orange powder, m.p. 135–136 C (from benzene); Yield
7%A, 31%C, 37%D; IR (cm1): 2956 (CH2), 1709 (C‚O);
1H NMR (CDCl3): 3.79 (2H, s, H-4), 7.22 (1H, t, J= 7.3,
H-40), 7.41–7.46 (5H, m, H-30,300,400,50,500), 7.75 (2H, dd,
3J= 6.6, 4J= 2.9, H-200,600), 7.97 (2H, d, J= 7.3, H-20,60);
13C NMR: 39.7 (C-4), 154.8 (C-3), 170.4 (C‚O), 119.2 (2C),
125.4, 126.1 (2C), 129.0 (2C), 129.96 (2C), 130.8, 130.9,
138.2 (sp2 carbons); MS: m/z (%) 236 (13) [M+]
(C15H12N2O), 237 (2) [M+1], 207 (1) [MCOH], 194 (3)
[MC2H2O], 103 (27) [MC7H5N2O], 91 (22) [194APhCN],
77 (83) [C6H5
+], 51 (100) [77AC2H2].
2.6. 1,3-Diphenyl-1H-pyrazol-5-ol (2bc)
Pale orange powder, m.p. 135–136 C (from benzene); Yield
7%A, 31%C, 37%D; IR (cm1): 2956 (CH2), 1709 (C‚O);
1H NMR (DMSO-d6): 6.05 (1H, s, H-4), 7.29–7.35 (2H, m,
H-40,400), 7.43 (2H, t, J= 7.9, H-300,500), 7.49 (2H, t, J= 8.1,
H-30,50), 7.85 (4H, d, J= 8.1, H-20,200,60,600). 11.84 (s, OH);
13C NMR: 85.7 (C-4), 150.1 (C-3), 154.3 (C-5) 121.7 (2C),
125.7 (2C), 126.2, 128.4, 129.1 (2C), 129.5 (2C), 134.0, 139.5
(sp2 carbons); MS: m/z (%) 236 (13) [M+] (C15H12N2O), 237
(2) [M+1], 207 (1) [MCOH], 194 (3) [MC2H2O], 103
(27) [MC7H5N2O], 91 (22) [194APhCN], 77 (83) [C6H5+],
51 (100) [77AC2H2].
2.7. 3-Methyl-1H-pyrazol-5-ol (2cc)
Colorless ﬁne needles, m.p. 217–219 C; Yield 53%A, 91%C,
83%D; IR (cm1): 2344–3000 ðNH nOHÞ; 1H NMR
(DMSO-d6): 2.08 (3H, s, CH3), 5.20 (1H, s, H-4), 10.41 (br.s,
NH nOH; 13C NMR: 11.7 (CH3), 89.5 (C-4), 139.9 (C-3),
161.6 (C-5); MS: m/z (%) 98 (100) [M+] (C4H6N2O), 99 (14)
[M+1], 97 (19) [MH], 83 (1) [MCH3], 70 (41) [MN2],
69 (47) [MCOH],56 (39) [MC2H2O], 55 (25) [56AH], 54
(54) [83AN2H].
2.8. 3-Phenyl-1H-pyrazol-5-ol (2dc)
White powder, m.p. 236–238 C; Yield 48%A, 90%C, 87%D;
IR (cm1): 2957 (CH2), 1709 (C‚O);
1H NMR (DMSO-d6):
5.92 (1H, s, H-4), 7.28 (1H, t, J= 7.7, H-400), 7.39 (2H, t,
J= 7.7, H-300,500), 7.67 (2H, d, J= 7.7, H-200,600), 11.02 (br.s,
NH nOH; 13C NMR: 87.4 (C-4), 143.9 (C-3), 161.6 (C-5),
125.3 (2C), 128.3, 129.3 (2C), 131.0 (sp2 carbons); MS: m/z
(%) 160 (100) [M+] (C9H8N2O), 161 (12) [M+1], 159 (16)
[MH], 131 (9) [MCOH], 118 (7) [MC2H2O], 103 (52)
[MCHN2O], 89 (3) [131AC2H2O], 77 (28) [C6H5+], 51 (25)
[77AC2H2].
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Colorless ﬁne needles, m.p. 213 C (from ethanol); Yield
43%A, 47%C, 50%D; IR (cm1): 2466-3066 (OH); 1H NMR
(DMSO-d6): 3.56 (3H, s, CH3), 5.79 (1H, s, H-4), 7.24 (1H,
t, J= 7.7, H-400), 7.35 (2H, t, J= 7.7, H-300,500),7.69 (2H, d,
J= 7.7, H-200,600), 11.08 (s, OH); 13C NMR: 39.9 (CH3), 83.7
(C-4), 148.1 (C-3), 153.7 (C-5), 125.1 (2C), 127.6, 129.0 (2C),
134.6 (sp2 carbons); MS: m/z (%) 174 (100) [M+]
(C10H10N2O), 175 (14) [M+1], 145 (3) [MCOH], 132 (6)
[MC2H2O], 131 (20) [159AN2], 103 (86) [MC2H3N2O], 77
(18) [C6H5
+], 51 (27) [77AC2H2].
2.10. 3-Ethyl-1H-pyrazol-5-ol (2fc)
Colorless ﬁne needles, m.p. 190 C; Yield 72%A, 66%C, 93%D;
IR (cm1): 2973 (CH2), 2367–2973 ðNH nOHÞ; 1H NMR
(DMSO-d6): 1.12 (3H, t, J= 7.4, CH3), 2.45 (2H, q,
J= 7.4,CH2), 5.24 (1H, s, H-4), 10.40 (br.s, NH/OH);
13C
NMR: 13.9 (CH3), 19.5 (CH2), 88.0 (C-4), 146.2 (C-3), 161.5
(C-5); MS: m/z (%) 112 (100) [M+] (C5H8N2O), 113 (13)
[M+1], 111 (15) [MH], 97 (64) [MCH3], 83 (6) [111AN2],
70 (8) [MC2H2O], 55 (72) [MCHN2O].
2.11. 3-Ethyl-1-methyl-1H-pyrazol-5(4H)-one (2gb)
Lemon yellow ﬁne needles, m.p. 104 C; Yield 59%A, 29%C,
60%D; IR (cm1): 2452–2967 (OH); 1H NMR (CDCl3): 1.16
(3H, t, J= 7.5,CH3), 2.41 (2H, q, J= 7.5, CH2), 3.26 (3H,
s, CH3), 3.16 (2H, s, CH2);
13C NMR: 10.9 (CH3), 31.1
(CH3), 24.5 (CH2), 39.9 (C-4), 160.3 (C-3), 172.3 (C‚O);
MS: m/z (%) 126 (54) [M+] (C6H10N2O), 127 (5) [M+1],
125 (2) [M-H], 111 (19) [MCH3], 97 (2) [MCOH], 84 (5)
[MC2H2O], 83 (17) [111AN2], 55 (100) [MC2H3N2O].
2.12. 3-Ethyl-1-methyl-1H-pyrazol-5-ol (2gc)
Lemon yellow ﬁne needles, m.p. 104 C; Yield 59%A, 29%C,
60%D; IR (cm1): 2452–2967 (OH); 1H NMR (DMSO-d6):
1.08 (3H, t, J= 7.7, CH3), 2.35 (2H q, J= 7.7, CH2), 3.38
(3H, s, CH3), 5.13 (1H, s, H-4), 10.76 (s, OH);
13C NMR:
14.0 (CH3), 32.7 (CH3), 22.0 (CH2), 151.7 (C-3), (the com-
pound was partially sol. so C-4 and C-5 did not appear);
MS: m/z (%) 126 (54) [M+] (C6H10N2O), 127 (5) [M+1],
125 (2) [MH], 111 (19) [MCH3], 97 (2) [MCOH], 84
(5) [MC2H2O], 83 (17) [111AN2], 55 (100) [MC2H3N2O].
2.13. 1-Methyl-3-(triﬂuoromethyl)-1H-pyrazol-5-ol (2hc)
Colorless ﬁne needles, m.p. 169–172 C (from benzene); Yield
28%A, 40%C, 72%D; IR (cm1): 1699 (C‚O); 1H NMR
(DMSO-d6): 3.59 (3H, s, CH3), 5.72 (1H, s, H-4) 11.70 (s,
OH); 13C NMR: 34.2 (CH3), 84.9 (C-4), 123.2 (q,
1JCF = 266, CF3), 138.6 (q,
2JCF = 37.0, C-3), 153.6 (C-5);
MS: m/z (%) 166 (100) [M+] (C5H5F3N2O), 167 (8) [M+1],
165 (17) [MH], 147 (35) [MF], 138 (24) [MN2], 123 (11)
[MC2H2OH], 95 (17) [MC2H3N2O], 69 (63) [CF3+].
2.14. 1-Phenyl-3-(triﬂuoromethyl)-1H-pyrazol-5-ol (2ic)
Beige powder, m.p. 191–192 C (from benzene); Yield 57%B,
72%C, 27%D; IR (cm1): 2400–3300 (OH); 1H NMR(DMSO-d6): 5.93 (1H, s, H-4), 7.38 (1H, t, J= 7.6, H-4
0),
7.51 (2H, t, J= 7.6, H-30,50), 7.72 (2H, d, J= 7.6, H-20,60),
12.47 (s, OH); 13C NMR: 86.2 (C-4),121.9 (q, 1JCF = 266.9,
CF3), 141.0 (q,
2JCF = 36.7, C-3), 154.3 (C-5), 122.8 (2C),
127.8, 129.6 (2C), 138.3 (sp2 carbons); MS: m/z (%) 228
(100) [M+] (C10H7F3N2O], 229 (13) [M+1], 209 (8) [MF],
199 (10) [MCOH], 184 (1) [MC2H2OH], 159 (4)
[MCF3], 131 (5) [159AN2], 77 (89) [C6H5+], 69 (13)
[CF3
+], 51 (6) [77AC2H2].
2.15. 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one (2jb)
Beige scales, m.p. 128 C (from ethanol); Yield 56%B, 56%C,
57%D; IR (cm1): 2612–3129 (OH); 1H NMR (CDCl3): 2.19
(3H, s, CH3), 3.42 (2H, s, CH2), 7.17 (1H, t, J= 7.8, H-4
0),
7.38 (2H, t, J= 7.8, H-30,50), 7.84 (2H, d, J= 7.8, H-20,60);
13C NMR: 17.1 (CH3), 43.2 (C-4), 156.3 (C-3), 170.6
(C‚O), 118.9 (2C), 125.1, 128.9 (2C), 138 1 (sp2 carbons);
MS: m/z (%) 174 (58) [M+] (C10H10N2O), 175 (18) [M+1],
145 (24) [MCOH], 103 (24) [MC2H3N2O], 91 (46) [145-
C2H3N2H], 82 (49) [MPhCH3], 77 (9) [C6H5+], 55 (100)
[82AN2+H], 51 (64) [77AC2H2].
2.16. 3-Methyl-1-phenyl-1H-pyrazol-5-ol (2jc)
Beige scales, m.p. 128 C (from ethanol); Yield 56%B, 56%C,
57%D; IR (cm1): 2612–3129 (OH); 1H NMR (DMSO-d6):
2.11 (3H, s, CH3), 5.36 (1H, s, H-4), 7.12 (1H, t, J= 7.7, H-
40), 7.41 (2H, t, J= 7.7, H-30,50), 7.71 (2H, d, J= 7.7, H-
20,60), 11.48 (s, OH); 13C NMR: 14.7 (CH3), 88.3 (C-4), 137.7
(C-3), 153.8 (C-5), 118.5 (2C), 121.2, 125.5 (2C), 129.4 (sp2 car-
bons); MS: m/z (%) 174 (58) [M+] (C10H10N2O), 175 (18)
[M+1], 145(24) [MCOH], 103 (24) [MC2H3N2O], 91
(46) [145C2H3N2H], 82 (49) [MPh], 77 (9) [C6H5+], 51
(64) [77AC2H2].
2.17. 3-Methyl-1-(pyridin-2yl)-1H-pyrazol-5-ol (2kc)
Beige powder, m.p. 104–106 C (from ethanol); Yield 15%B,
24%C, 4%D; IR (cm1): 2792–3053 (OH); 1H NMR (CDCl3):
2.23 (3H, s, CH3), 5.42 (1H, s, H-4), 7.11(1H, td,
3J= 8.1,
4J= 2.7, H-50), 7.83–7.85 (2H, m, H-30,40), 8.23 (1H, d,
J= 4.4, H-60), 12.75 (s, OH); 13C NMR: 14.7 (CH3), 88.4 (C-
4), 151.7 (C-3), 157.0 (C-5), 111.9, 119.6, 139.9, 145.2, 154.5
(sp2 carbons); MS: m/z (%) 175 (100) [M+] (C9H9N3O), 176
(19) [M+1], 160 (20), [MACH3], 146 (7) [MCOH],
134 (53) [MC2H2O+H], 118 (9) [134ACH3H], 79 (54)
[134AC2H3N2].
2.18. 3-Phenyl-1-(pyridin-2yl)-1H-pyrazol-5-ol (2lc)
Violet needles, m.p. 119 C (from ethanol); Yield 72%B,
65%C; IR (cm1): 3075–3137 (OH); 1H NMR (CDCl3): 5.94
(2H, s, H-4), 7.13 (1H, dd, 3J4
00
;5 = 7,
3J05,6
0 = 5.8, H-50), 7.35
(1H, t, J= 7.5, H-400), 7.41 (2H, t, J= 7.5, H-300,500), 7.84–
7.87 (3H, m, H-200,40,600), 8.02 (1H, d, 3J= 8.0, H-30), 8.24
(1H, d, 3J= 4.4, H-60), 12.81 (s, OH); 13C NMR: 85.8 (C-4),
145.2 (C-3), 157.3 (C-5), 112.3, 120.0, 125.9 (2C), 128.6,
128.7 (2C), 133.2, 140.0, 152.7, 154.6. (sp2 carbons); MS: m/z
(%) 237 (100) [M+] (C14H11N3O), 238 (17) [M+1], 236 (11)
[MH], 208 (4) [MCOH], 196 (13) [MC2H2O+H], 160
(3) [MPh].
290 A.A. Al-Mutairi et al.2.19. 60-Amino-1,30-disubstituted-20H-spiropiperidine-4,40-
pyrano[2,3-c]pyrazole-50-carbonitrile (3a–c)
2.19.1. Method A: for synthesis of 3a–c
They were prepared as reported (Shestopalov et al., 2002,
2003).
2.19.2. Method B: for synthesis of 3a
They were prepared as reported (Shestopalov et al., 2002,
2003).
2.19.3. Method C: for synthesis of 3a–c
A solution of the corresponding 1-substituted piperidin-4-one
(0.01 mol), malononitrile (0.66 g, 0.01 mol), 2c or 2f
(0.01 mol) and triethylamine (0.5 mL) in absolute ethanol
(25 ml) was placed in a 25 mL conical ﬂask, then irradiated
in the water bath of an ultrasonic cleaner for 5–10 min. The so-
lid product formed was ﬁltered off, washed with ethanol and
hexane, dried and recrystallized from ethanol.
2.20. 60-Amino-1,30-dimethyl-20H-spiro[piperidine-4,40-
pyrano[2,3-c]pyrazole]-50-carbonitrile (3a)
Beige powder, m.p. 154 C; Yield 12%A, 53%B, 26%C; IR
(cm1): 2184 (CN), 3318, 3259 (NH2);
1H NMR (DMSO-d6):
1.71 (2H, d, J= 13.1, Hax-3,5), 2.07 (2H, td, J= 13.1,
J= 3.5, Heq-3,5), 2.23 (3H, s, NCH3), 2.25 (3H, s, CH3),
2.57–2.60 (2H, m, Hax-2,6), 2.76 (2H, td, J= 13.1, J= 3.5,
Heq-2,6), 6.63 (s, NH2), 12.07 (s, NH);
13C NMR: 12.3 (CH3),
31.0 (C-4), 40.1 (C-3/C-5), 46.6 (CH 3), 51.5 (C-2/C-6), 60.7
(C-50), 103.4 (30a), 124.5 (CN), 134.7 (C-30), 155.0 (70a), 162.3
(C-60); MS: m/z (%) 134 (17) [MC3H2N2OCH3N2], 119
(100) [134ACH3], 102 (12) [119ANH3], 91 (23) [119AHCN].
2.21. 60-Amino-1-benzyl-30-methyl-20H-spiro[piperidine-4,40-
pyrano[2,3-c]pyrazole]-50-carbonitrile (3b)
Pale yellow powder, m.p. 132 C; Yield 16%B, 48%C; IR
(cm1): 2179 (CN), 3382, 3312 (NH2);
1H NMR (DMSO-d6):
1.74 (2H, d, J= 12.3, Hax-3,5), 2.08 (2H, td, J= 12.3,
J= 4.4, Heq-3,5), 2.28 (3H, s, CH3), 2.66 (2H, d, J= 12.3,
Hax-2,6), 2.86 (2H, t, J= 12.3, Heq-2,6), 3.55 (2H, s, CH2-
Ph), 6.69 (s, NH2), 7.24-7.33 (5H, m, ph), 12.11 (s, NH);
13C
NMR: 12.4 (CH3), 31.6 (C-4), 40.1 (C-3/C-5), 49.5 (C-2/C-6),
60.7 (C-50), 62.9 (CH2), 103.4 (30a), 124.6 (CN), 134.8 (C-300),
155.0 (70a), 162.3 (C-60), 127.4, 128.7 (2C), 129.2 (2C), 139.3
(sp2 carbons); MS: m/z (%) 335 (1) [M+] (C19H21N5O), 336
(2) [M+1], 337 (2) [M+2], 308 (2) [MHCN], 174 (12)
[MC7H6N4O+H], 91 (100) [C7H7+].
2.22. 60-Amino-30-ethyl-1-methyl-20H-spiro[piperidine-4,40-
pyrano[2,3-c]pyrazole]-50-carbonitrile (3c)
White scales, m.p. 144 C; Yield 62%B, 50%C; IR (cm1): 2180
(CN), 3273, 3129 (NH2);
1H NMR (DMSO-d6):1.19 (3H, t,
J= 7.3, CH3CH2), 1.71 (2H, d, J= 12.8, Hax-3,5), 2.08
(2H, td, J= 12.8, J= 4.4, Heq-3,5), 2.23 (3H, s, NCH3),
2.62-2.68 (4H, m, CH3CH2, Hax-2,6), 2.77 (2H, t, J= 12.8,
Heq-2,6), 6.67 (s, NH2), 12.12 (s, NH);
13C NMR: 14.0(CH3),
19.5 (CH2), 31.1 (C-4), 40.2 (C-3/C-5), 46.7 (CH3), 51.6 (C-2/
C-6), 60.6 (C-50), 103.0 (30a), 124.6 (CN), 140.4 (C-30), 154.8(70a), 162.3 (C-60); MS: m/z (%) 273 (6) [M+] (C14H19N5O),
274 (2) [M+1], 206 (16) [MC2H2NH2+H], 160 (17)
[206AC2H5CH32H], 112 (33) [206AC6H11N+3H], 83 (14)
[112AC2H5], 71 (100) [112AC2H2O+H].
2.23. 6-Amino-4-(40-substitutedphenyl)-1,3-dimethyl-1,4-
dihydropyrano[2,3-c]pyrazole-5-carbonitrile (4a,b)
2.23.1. Method A: for synthesis of 4a,b
They were prepared as reported (Sharanin et al., 1982).
2.23.2. Method B: for synthesis of 4a,b
They were prepared as reported (Sharanin et al., 1982).
2.23.3. Method C: for synthesis of 4a,b
A solution of the 2a (1.12 g, 0.01 mol) and arylidenemalono-
nitrile (0.01 mol) in methanol (50 ml) was placed in a 100 mL
conical ﬂask, and was then irradiated in the water bath of an
ultrasonic cleaner for 30–45 min. The solid product formed
was ﬁltered off, washed with ethanol, dried and recrystallized.
2.24. 6-Amino-4-(40-chlorophenyl)-1,3-dimethyl-1,4-
dihydropyrano[2,3-c]pyrazole-5-carbonitrile (4a)
Colorless ﬁne needles, m.p. 147 C (from ethanol); Yield
26%A, 10%B, 16%C; IR (cm1): 2201 (CN), 3297, 3142
(NH2);
1H NMR (DMSO-d6): 1.67 (3H, s, CH3 at position
3), 3.60 (3H, s, CH3 at position 1), 4.62 (1H, s, H-4), 7.14
(2H, s, NH2), 7.21 (2H, d, J= 8.1, H-2
0,60, AA0 part of
AA0XX0 system), 7.39 (2H, d, J= 8.1, H-30,50, XX0 part of
AA0XX0 system); 13C NMR: 12.9 (CH3 at position 3), 34.0
(CH3 at position 1), 37.0 (C-4), 58.3 (C-5), 96.2 (C-3a), 120.7
(CN), 143.0 (C-7a), 144.8 (C-3), 160.1 (C-6) 129.0 (2C),
130.1 (2C), 131.9, 143.6 (sp2 carbons); MS: m/z (%) 300 (12)
[M+] (C15H13
35ClN4O), 302 (4) [M+2] (C15H13
37ClN4O),
234 (9) [MCNCH3CN+H], 189 (100) [MC6H4Cl].
2.25. 6-Amino-4-(40-methoxyphenyl)-1,3-dimethyl-1,4-
dihydropyrano[2,3-c]pyrazole-5-carbonitrile (4b)
White powder, m.p. 135 C (from ethanol); Yield 15%A,
46%B, 9%C; IR (cm1): 2192 (CN), 3323, 3183 (NH2);
1H
NMR (DMSO-d6): 1.68 (3H, s, CH3 at position 3), 3.61 (3H,
s, CH3 at position 1), 3.75 (3H, s, OCH3), 4.54 (1H, s, H-4),
7.05 (2H, s, NH2), 6.89 (2H, d, J= 7.9, H-3
0,50, AA0 part of
AA0XX0 system). 7.10 (2H, d, J= 7.9, H-20,60, XX0 part of
AA0XX0 system); 13C NMR: 13.0 (CH3 at position 3), 34.0
(CH3 at position 1), 37.0 (C-4), 55.6 (OCH3), 58.2 (C-5),
96.9 (C-3a), 120.9 (CN), 144.7 (C-3), 143.1 (C-7a), 159.9 (C-
6), 114.3 (2C), 129.2 (2C), 136.6, 158.6 (sp2 carbons).
2.26. 5-Hydroxy-1-methyl-3-substituted-N-phenyl-1H-pyrazole-
4-carbothioamide (5a,b)
2.26.1. Method A: for synthesis of 5a,b
They were prepared as reported (Abd EL-Rahman et al.,
2009).
2.26.2. Method B: for synthesis of 5a,b
They were prepared as reported (Abd EL-Rahman et al.,
2009).
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carbothioamide (5a)
Yellow ﬁne needles, m.p. 126 C (from ethanol); Yield 74%A,
76%B; IR (cm1): 1086 (C‚S), 3174–2612 (NH/OH); 1H
NMR (CDCl3): 3.74 (3H, s, CH3), 7.18-7.21 (1H, m, H-4
00),
7.29–7.32 (4H, m, H-200,300,500,600), 7.51–7.55 (3H, m, H-
40,30,50), 7.62 (2H, d, J= 6.9, H-20,60), 8.59 (s, OH), 12.6
(br.s, NH); 13C NMR: 33.6 (CH3), 154.5 (C-3), 99.2 (C-4),
158.6 (C-5), 186.3 (C‚S), 124.0 (2C), 126.9, 129.0 (2C),
129.5 (2C), 129.6 (2C), 130.0, 133.2, 137.5 (sp2 carbons); MS:
m/z (%) 309 (67) [M+] (C17H15N3O S), 310 (15) [M+1], 276
(52) [MSH], 216 (100) [MphNH2], 93 (80) [MC11-
H9N2OS+H].
2.28. 3-Ethyl-5-hydroxy-1-methyl-N-phenyl-1H-pyrazole-4-
carbothioamide (5b)
Yellow powder, m.p. 130 C (from benzene); Yield 94%A,
75%B; IR (cm1): 1087 (C‚S), 3145–2610 (NH/OH); 1H
NMR (DMSO-d6): 1.25 (3H, t, J= 7.3, CH3), 3.22 (2H, q,
J= 7.3, CH2), 3.40 (3H, s, CH3 at position 1), 7.20 (1H, t,
J= 7.7, H-400), 7.39 (2H, t, J= 7.7, H-300,500), 7.81 (2H, d,
J= 7.7, H-200,600), 13.3 (br.s, NH); 13C NMR: 13.0 (CH3),
21.3 (CH2), 30.1 (CH3 at position 1), 103.2 (C-4), 153.4 (C-
3), 160.6 (C-5), 187.0 (C‚S), 123.8 (2C), 125.8, 129.1 (2C),
139.9 (sp2 carbons); MS: m/z (%) 261 (41) [M+]
(C13H15N3O S), 262 (27) [M+1], 228 (32) [MSH], 109 (59)
[MC7H6NSCH3H], 93 (73) [MC7H9N2OS+H], 67
(32) [MC6H5+H], 51 (100) [MC2H2+H].
2.29. 1,3-Disubstituted-4-(2-oxo-1,2-diphenylethylidene)-1H-
pyrazol-5(4H)-one (6a–c)
They were prepared as reported (Da-Ming et al., 1995).
2.30. 1,3-Dimethyl-4-(2-oxo-1,2-diphenylethylidene)-1H-
pyrazol-5(4H)-one (6a)
Orange powder, m.p. 116–118 C (from hexane); Yield 35%,
IR (cm1): 1670, 1692 (2 C‚O), 1H NMR (CDCl3): 1.82
(3H, s, CH3 at position 3), 3.26 (3H, s, CH3 at position 1),
7.44–7.60 (8H, m, H-300,400,500,2000,3000,4000,5000,6000), 7.95 (2H, cou-
pling is not resolved, H-200,600); 13C NMR: 16.9 (CH3 at posi-
tion 3), 31.2 (CH3 at position 1), 130.8 (C-4), 146.4 (C-3),
157.1 (C-6), 163.5 (C‚O at C-5), 195.2 (C‚O of benzoyl
gp) 127.1, 128.7 (2C), 129.0 (6C), 132.3, 134.0, 134.6 (sp2 car-
bons); MS: m/z (%) 304 (25) [M+] (C19H16N2O2), 305 (11)
[M+1], 261 (100), [MCH3CN2H], 237 (100)
[MCH3CNHCN+H], 201 (30) [MPhCO+2H].
2.31. 3-Ethyl-1-methyl-4-(2-oxo-1,2-diphenylethylidene)-1H-
pyrazol-5(4H-(one (6b)
Dark orange needles, m.p. 110–112 C (from hexane); Yield
29%; IR (cm1): 1666, 1694 (2 C‚O); 1H NMR (CDCl3):
0.92 (3H, t, J= 7.3, CH3), 2.16 (2H, q, J= 7.3, CH2), 3.26
(s, CH3 at position 1), 7.39–7.55 (8H, m, H-
2000,300,400,500,6000,3000,4000,5000), 7.94 (2H, d, J= 8.1, H-200,600); 13C
NMR: 10.6 (CH3), 23.8 (CH2), 31.3 (CH3 at position 1),
130.7 (C-4), 151.0 (C-3), 156.8 (C-6), 163.7 (C‚O at C-5),
195.4 (C‚O of benzoyl gp). 126.8, 128.4 (2C), 129.0 (6C),132.7, 133.9, 134.6 (sp2 carbons); MS: m/z (%) 318 (9) [M+]
(C20H18N2O2), 319 (2) [M+1], 289 (5) [MEt], 275 (80)
[289ACH3+H], 247 (12) [MC2H5CNCH3H], 105 (100)
[Ph–C„O+].
2.32. 3-Methyl-4-(2-oxo-1,2-diphenylethylidene)-1-phenyl-1H-
pyrazol-5(4H)-one (6c)
Orange needles, m.p. 170 C (from hexane); Yield 49%; IR
(cm1): 1667, 1691 (2 C‚O); 1H NMR (CDCl3): 1.92 (3H,
s, CH3), 7.12 (1H, t, J= 7.7, H-4
0), 7.32 (2H, t, J= 8.2, H-
400,4000), 7.42-7.56 (8H, m, H-20,30,50,60,300,500,3000,5000), 7.83 (2H,
dd, J =8.2, J= 1.5, H-2000,6000), 7.97 (2H, d, 3J= 8.2,
4J= 1.5, H-200,600); 13C NMR: 17.1 (CH3), 130.9 (C-4), 148.0
(C-3), 157.8 (C-6), 162.0 (C‚O at C-5), 195.1 (C‚O of ben-
zoyl gp), 118.6 (2C), 125.1, 127.9, 128.7 (2C), 128.8 (2C),
129.0 (2C), 129.1 (4 C), 132.3, 134.1, 134.4, 137.8 (sp2 car-
bons); MS: m/z (%) 366 (9) [M+] (C24H18N2O2), 367 (4)
[M+1], 365 (3) [MH], 261 (40) [MPhCO], 233 (11)
[261AHCN2H], 105 (87) [Ph–C„O+], 77 (100) [C6H5+].
2.33. 4-Arylazo-1,3-disubstituted-1H-pyrazol-5-ol (7ª–f)
Diazonium salt [prepared by adding a solution of sodium ni-
trite (0.41 g, 0.006 mol) to ice cold solution of the correspond-
ing aromatic amine (0.006 mol) in 2 M HCl (9 mL)] was added
to a cold solution of 2a,e,j (0.006 mol) in absolute ethanol
(30 mL), containing sodium acetate (3 g), drop wise with stir-
ring at 0–5 C. The reaction mixture was stirred at room tem-
perature for 3 h and the precipitated crude product was
ﬁltered, washed with water, dried and recrystallized.
2.34. 4-[(3-Methoxyphenyl)diazenyl]-1,3-dimethyl-1H-
pyrazol-5-ol (7a)
Orange needles, m.p. 107–108 C (from ethanol); Yield 73%;
IR (cm1): 1471 (N‚N), 1593 (C‚N), 1660 (C‚O); 1H
NMR (CDCl3): 2.21 (3H, s, CH3 at position 3), 3.35 (3H, s,
CH3 at position 1), 3.80 (3H, s, OCH3), 6.94 (1H, t,
4J= 1.2, H-200), 6,68 (1H, dd, 3J= 7.5, 4J= 1.2, H-400), 7.24
(1H, t, J= 7.5, H-500), 6.89 (1H, dd, 3J= 7.5, 4J= 1.2, H-
600), 13.40 (s, OH); 13C NMR: 11.7 (CH3 at position 3), 31.0
(CH3 at position 1), 55.5 (OCH3), 128.4 (C-4), 147.1 (C-3),
158.6 (C-5), 101.0, 108.4, 111.3, 130.5, 142.5, 160.9 (sp2 car-
bons); MS: m/z (%) 246 (26) [M+] (C12H14N4O2), 91 (87)
[MOCH3C5H7N3O+H], 55 (100) [MC7H7N2O
CON2].
2.35. 4-[(3-Ethylphenyl)diazenyl]-1,3-dimethyl-1H-pyrazol-
5-ol (7b)
Yellowish orange powder, m.p. 110 C (from ethanol); Yield
60%; IR (cm1): 1499 (N‚N), 1592 (C‚N), 1661 (C‚O);
1H NMR (CDCl3): 1,26 (3H, t, J= 7.5, CH3), 2.26 (3H, s,
CH3 at position 3), 3.39 (3H, s, CH3 at position 1), 2.68
(2H, q, J= 7.5, CH2), 7.21-7.23 (2H, m, H-2
00,600), 7.02 (1H,
d, J= 7.99, H-400), 7.30 (1H, t, J= 7.9, H-500), 13.40 (s,
OH); 13C NMR: 11.8 (CH3 at position 3), 15.5 (CH3), 28.9
(CH2), 31.0 (CH3 at position 1), 129.6 (C-4), 147.2 (C-3),
158.7 (C-5), 113.2, 115.2, 125.4, 129.6, 141.3, 146.2 (sp2
carbons).
292 A.A. Al-Mutairi et al.2.36. 4-[(3-Ethylphenyl)diazenyl]-3-phenyl-1-methyl-1H-
pyrazol-5-ol (7c)
Dark orange needles, m.p. 149 C (from methanol); Yield
89%; IR (cm1): 1499 (N‚N), 1591 (C‚N), 1654 (C‚O);
1H NMR (CDCl3): 3.52 (3H, s, CH3 at position 1), 1.27 (3H,
t, J= 7.7, CH3), 2.69 (2H, q, J= 7.5, CH2), 7.25 (1H, d,
4J= 2.2, H-200), 7.05 (1H, d, J= 6.6, H-400), 7.28–7.48 (5H,
m, H-30,40,50,500,600), 8.11 (2H, d, J= 6.6, H-20,60), 13.90, (s,
OH); 13C NMR: 15.4 (CH3),28.9 (CH2), 31.5 (CH3 at position
1), 129.5 (C-4), 146.2 (C-3), 158.9 (C-5), 113.4, 115.6,125.7,
126.9, 127.2 (2C), 128.6 (2C), 129.7, 130.8, 141.3 (sp2 carbons).
2.37. 4-[(3-Methoxyphenyl)diazenyl]-3-methyl-1-phenyl-1H-
pyrazol-5-ol (7d)
Orange needles, m.p. 126 C (from methanol); Yield 81%; IR
(cm1): 1496 (N‚N), 1607 (C‚N), 1661 (C‚O); 1H NMR
(CDCl3): 2.30 (3H, s, CH3), 3.79 (3H, s, OCH3), 6.95 (1H, t,
4J= 1.9, H-200), 6.68 (1H, dd, 3J= 7.2, 4J= 1.9, H-400), 7.17
(1H, t, J= 7.2, H-500), 6.90 (1H, dd, 3J= 7.2, 4J= 1.9, H-
600), 7.25 (1H, t, J= 8.3, H-40), 7.39 (2H, t, J= 8.3, H-30,50),
7.94 (2H, d, J= 8.3, H-20,60), 13.44 (s, OH); 13C NMR: 11.9
(CH3), 55.5 (OCH3), 128.5 (C-4), 148.6 (C-3), 157.7 (C-5),
101.2, 108.5, 111.5, 118.4 (2C), 125.1, 129.0 (2C), 130.5,
138.1, 142.4, 160.9 (sp2 carbons).
2.38. 4-[(4-Ethoxyphenyl)diazenyl]-3-methyl-1-phenyl-1H-
pyrazol-5-ol (7e)
Orange powder, m.p. 147 C (from methanol); Yield 93%; IR
(cm1): 1499 (N‚N), 1593 (C‚N), 1653 (C‚O); 1H NMR
(CDCl3): 0.67 (3H, t, J= 7.3, CH3), 1.84 (3H, s, CH3 at positio
3), 3.32 (2H q, J= 7.3, OCH2), 6.23 (2H, d, J= 8.1, H-3
00,500,
AA0 part of AA0XX0 system), 6.45 (1H, t, J= 7.3, H-40), 6.66
(2H, t, J= 7.3, H-30,50), 6.74 (2H, d, J= 8.1, H-200,600, XX0
part of AA0XX0 system), 7.21 (2H, d, J= 7.3, H-20,60); 13C
NMR: 11.3 (CH3 at position 3), 14.3 (CH3), 63.2 (OCH2),
126.5 (C-4), 147.6 (C-3), 156.8, 157.0 (C-5), 115.0 (2C), 117.1
(2C), 117.6 (2C), 124.3, 128.4 (2C), 134.2,137.8 (sp2 carbons).
2.39. 4-[(3-Ethylphenyl) diazenyl]-3-methyl-1-phenyl-1H-
pyrazol-5-ol (7f)
Orange needles, m.p. 122 C (from ethanol); Yield 76%; IR
(cm1): 1499 (N‚N), 1592 (C‚N), 1662 (C‚O); 1H NMR
(CDCl3): 2.37 (3H, s, CH3), 1.27 (3H, t, J= 7.7,), 2.69 (2H
q, J= 7.7, CH2), 7.24–7.26 (2H, m, H-2
00,600), 7.05 (1H, d,
J= 7.3, H-400), 7.20 (1H, t, J= 7.3, H-500), 7.32 (1H, t,
J= 7.7, H-40), 7.43 (2H, t, J= 7.7, H-30,50), 7.96 (2H, d,
J= 7.7, H-20,60), 13.69 (s, OH); 13C NMR: 11.9 (CH3 at posi-
tion 3), 15.5 (CH3), 28.9 (CH2), 128.3 (C-4), 148.6 (C-3), 157.9
(C-5), 113.4, 115.3, 118.6 (2C), 125.2, 125.7, 129.0 (2C), 129.7,
138.2, 141.2, 146.3 (sp2 carbons).
2.40. 4,40-(Arylmethylene)bis-1,3-disubstituted-1H-pyrazol-5-ol
(8a,b)
2.40.1. Method A: for synthesis of 8a,b
A mixture of 2j (0.002 mol, 0.348 g), vanilline (0.002 mol,
0.304 g) and distilled water (10 mL) was stirred at room tem-perature for 5 min, the solid crystal product was ﬁltered and
washed with water. It was pure and did not need
recrystallization.
2.40.2. Method B: for synthesis of 8a,b
They were prepared as reported (Wang et al., 2005).
2.40.3. Method C: for synthesis of 8a,b
A mixture of 2j (0.01 mol), the appropriate aromatic aldehyde
(0.01 mol) and piperidine (three drops) in absolute ethanol
(30 mL) was placed in a 100 mL conical ﬂask. The mixture
was then irradiated in the water bath of an ultrasonic cleaner
for 5–17 min. The solid product was ﬁltered off, washed with
ethanol, dried and recrystallized.
2.41. 4,40-(4-Hydroxy-3-methoxyphenyl)methylenebis-3-
methyl-1-phenyl-1H-pyrazol-5-ol (8a)
Pale yellow cubes, m.p. 199 C; Yield 14%A, 18%B, 33%C; IR
(cm1): 3168–2648 (OH); 1H NMR (DMSO-d6): 2.32 (6H, s,
2CH3), 3.68 (3H, s, OCH3), 4.86 (1H, s, methine-H), 6.70–
6.71 (2H, m, H-500,600), 6.88 (1H, s, H-200), 7.25 (2H, t,
J= 8.2, 2H-40), 7.45 (4H, t, J= 8.2, 2H-30,50), 7.72 (4H, dd,
3J= 8.2, 4J= 1.4, 2H-20,60), 8.78 (s, OH), 14.04 (s, OH);
13C NMR: 12.3 (2CH3), 34.0 (methine-C), 56.2 (OCH3),
112.5, 146.7 (2C-3),115.7,120.2, 121.2 (4C), 126.1 (2C), 129.5
(4C), 133.9, 137.0 (2C), 145.5, 147.8 (sp2 carbons) (C-4 and
C-5 are within the base line); MS: m/z (%) 484 (21)
[M+2H], 120 (100) [MH2OC10H8N2C8H8N2OCH3
CO+4H], 91 (79) [azatropylium ion].
2.42. 4,40-(3,4,5-Trimethoxyphenyl)methylenebis3-methyl-1-
phenyl-1H-pyrazol-5-ol (8b)
Colorless needles, m.p. 199 C (from ethanol); Yield 5%A,
9%B, 32%C; IR (cm1): 3138–2562 (OH); 1H NMR
(DMSO-d6): 2.50 (6H, s, 2CH3), 3.62 (3H, s, OCH3), 3.69
(6H, s, 2 OCH3), 4.86 (1H, s, methine-H), 6.68 (2H, s, H-
200,600), 7.26 (2H, t, J= 7.7, 2H-40), 7.45 (4H, t, J= 7.7, 2H-
30,50), 7.70 (4H, d, J= 7.7, 2H-20,60), 14.21 (s, OH); 13C
NMR: 12.3 (2CH3), 34.0 (methine-C), 56.4 (2 OCH3), 60.5
(OCH3), 146.7 (2C-3), 105.4 (2C), 121.3 (4C), 126.2 (2C),
129.5 (4C),136.5, 139.2 (2C), 146.8, 153.1 (2C); (sp2 carbons)
(C-4 and C-5 are within the base line); MS: m/z (%) 352 (34)
[MH2OC10H8N2], 321 (4) [MC20H20N2O2H], 219 (7)
[352C8H8N2H], 174 (47) [352AC10H12O3H], 105 (18)
[174AC4H5O], 91 (57) [azatropylium ion], 77 (100) [C6H5
+].
2.43. 3-Methyl-1-phenyl-Z-4-(araylidene)-1H-pyrazol-5(4H)-
one (9a,b)
A mixture of 2j (0.01 mol, 1.74 g), aromatic aldehyde
(0.01 mol) and piperidine (three drops) was heated under reﬂux
for 15 min, after cooling the solid product formed was ﬁltered,
washed with ethanol, and recrystallised from ethanol.
2.44. Z-4-(40-hydroxy-30-methoxybenzylidene)-3-methyl-1-
phenyl-1H-pyrazol-5(4H)-one (9a)
Red plates, m.p. 171–172 C; Yield 37%; IR (cm1): 3294
(OH), 1655 (C‚O), 1598 (C‚C); 1H NMR (DMSO-d6):
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3J= 8.0,
4J= 2.0, H-600), 7.19 (1H, t, J= 8.0, H-40), 7.44 (2H, td,
3J= 8.0, 4J= 2.0, H-30,50), 7.68 (1H, s, C‚CH), 7.94–7.97
(3H, m, H-20,60,500), 8.88 (1H, s, H-200), 10.45 (s, OH); 13C
NMR: 13.7 (CH3), 56.2 (OCH3), 131.8 (C-4), 147.9 (oleﬁnic
carbon), 152.3 (C-3), 162.6 (C-5), 116.1, 117.6, 119.0 (2C),
123.1, 124.9, 126.0, 129.3 (2C), 139.0, 149.5, 153.5 (sp2 car-
bons); MS: m/z (%) 308 (100) [M+] (C18H16N2O3), 309 (21)
[M+1], 307 (32) [MH], 185 (54) [MC7H7O2], 175 (26)
[MC8H8N2H], 115 (17) [185Ph+H].
2.45. Z-3-methyl-1-phenyl-4-(30,40,50-trimethoxybenzylidene)-
1H-pyrazol-5(4H)-one (9b)
Orange needles, m.p. 141–142 C; Yield 11%; IR (cm1): 1676
(C‚O), 1596 (C‚C); 1H NMR (DMSO-d6): 2.33 (s, CH3),
3.81 (s, OCH3), 3.87 (s, 6H, 2OCH3), 7.21 (1H, t, J= 7.6,
H-40), 7.45 (2H, t, J= 7.6, H-30,50), 7.77 (1H, s, C‚CH),
7.90 (2H, d, J= 7.6, H-20,60), 8.22 (2H, s, H-200,600); 13C
NMR: 13.7 (CH3), 56.2 (2OCH3), 60.9 (OCH3), 138.7 (C-4),
149.3 (oleﬁnic carbon), 152.4 (C-3), 162.3 (C-5), 112.6 (2C),
119.2 (2C), 125.2, 125.8, 129.0, 129.4 (2C), 142.8, 152.9 (2C)
(sp2 carbons); MS: m/z (%) 352 (76) [M+] (C20H20N2O4),
353 (14) [M+H], 351 (10) [MH], 219 (16) [MC8H8N2H],
185 (42) [MC9H11O3], 115 (11) [185APh+H], 77 (100)
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Scheme3. Results and discussion
Herein, we have synthesized a series of pyrazolones (2a–l) fol-
lowing conventional (Vogel, 1966) and ultrasound (Mojtahedi
et al., 2008) methods, which gave the products in moderate to
good yields. In addition, some of the target compounds were
prepared by the fusion method (Fitton and Smalley, 1968)
which was not efﬁcient. Furthermore, we have applied the
free-solvent microwave (MW) irradiation method for the ﬁrst
time in order to prepare these starting materials which led to
comparable yields to the above mentioned techniques. Synthe-
sis of pyrazolones following the MW procedure proved to give
the products 2a–l in relatively high purity, and accordingly
these starting materials were often used directly in the follow-
ing reactions without any further puriﬁcation. The synthetic
procedures adopted to obtain 2a–l are depicted in Scheme 1.
5-Pyrazolones appear in solution in three different tautomeric
forms (NH-form, CH-form and OH-form) (Shestopalov et al.,
2003) which were easily identiﬁed in NMR spectra. Character-
ization of pyrazolones (2a–l) was based on IR, 1H, 13C NMR
and mass spectral data. The IR spectra of 2a,c,e–g,i–l dis-
played broad absorption bands of the OH/NH stretching in
the region of 2344–3300 cm1 (in the solid state, these deriva-
tives are present in the OH-form) which were shifted to lower
frequencies due to strong hydrogen bonds (Refn, 1961; Katri-
tzky and Maine, 1964), the IR spectra of 2b,d,h displayedH2NHR
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(i) a: 1-substituted piperidin-4-one, CH2(CN)2, Et3N, stirring, RT, 20-24 h (3a-c); 
b: 1-substituted piperidin-4-one, CH2(CN)2, Et3N, reflux, 10 min (3a);  
c: 1-substituted piperidin-4-one, CH2(CN)2, Et3N, US 5-15 min (3a-c). 
(ii) a: 2-arylidenemalononitrile, MeOH, stirring, 30-35ºC, 2-5 h ;  
b: 2-Arylidenemalononitrile, morpholine, overnight,  
c: 2-arylidenemalononitrile, MeOH, US, 30-45 min 
(iii) a: PhNCS, DMF/KOH, HCl, stirring, RT, 20-24 h;  
b: PhNCS, DMF/KOH, HCl, US, 1h.
(iv) benzil, fusion, 180°C, 0.5-2 h 
(v) aryl amine, NaNO2, HCl, NaOAc, EtOH, stirring, RT, 3 h 
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Figure 1 Tautomeric forms of compound 3.
294 A.A. Al-Mutairi et al.bands at the range of 1699–1709 cm1 due to C‚O absorption
at position 5 (in the solid state, these derivatives are present in
the CH-form). All other spectral analyses match the structures
of the prepared pyrazolones (see Section 2).
In recent years, ultrasound has increasingly been used in or-
ganic synthesis (Al-Alshaikh, 2009). In this work, we subjected
pyrazolones to versatile reactions and we decided ﬁrst to use
the ultrasoniﬁcation procedure which has been rarely used in
the synthesis of pyrazolone derivatives. However, some of
the reactions of pyrazolones (Scheme 2) only gave poor yields,
Figure 2 Perspective view of the X-ray structure of 3c.
N
S
N
N
CH 3
OH
H
125.8129.1
123.8
139.9
187.0
103.2
160.6
30.1
153.4
13.0 21.3
Figure 3 13C NMR data of 5b.
Microwave versus ultrasound assisted synthesis of some new heterocycles based on pyrazolone moiety 295but moderate yields were obtained by thermal methods. One
pot multicomponent condensation reaction of 2e,f with malon-
onitrile and 1-substituted piperidine-4-one in the presence of
triethylamine at room temperature for 20–24 h with stirring
led to the formation of 3a–c, the reaction was monitored by
TLC. Compound 3a was prepared in one pot reaction by reﬂux
for 3 h as reported earlier (Shestopalov et al., 2003). On apply-
ing ultrasound, compounds 3a–c were also obtained, although
in comparable yields but highly pure and in a shorter time (5–
15 min). IR spectra of 3a–c displayed two characteristic bands
at 2179–2184, 3129–3312, and 3272–3382 cm1, due to absorp-
tion of CN and NH2 groups, respectively. The mass spectra of
these compounds gave the expected molecular ions (see Section
2), whereas their 1H NMR spectra exhibited two D2O
exchangeable signals at d 6.63–6.69 ppm and at d 12.07–
12.12 ppm ascribed for NH2 and NH group, respectively.
The spectrum of 3b also showed two doublet signals at d
2.66 ppm and d 1.74 ppm (J= 12.3 Hz) corresponding to the
four axial protons of methylene groups of piperidine moiety
at positions 2,6 and 3,5, respectively. The signal of the two
equatorial protons in piperidine moiety at positions 2,6 ap-peared as a triplet at d 2.86 ppm (J= 12.3 Hz), while the sig-
nal of the two equatorial protons in piperidine at positions 3,5
appeared as a triplet of doublet at d 2.08 ppm (J= 12.3,
4.4 Hz). Furthermore, 13C NMR conﬁrmed the structure of
3a–c, where the key signals at dC 31.0–30.6 were assigned to
the quaternary sp3 carbons, 124.5–124.6 to nitrile carbons,
N
N O
H3C
H
Ar
 Ar
 a  3-OCH3-4-OH-C6H3
b   3,4,5-OCH3-C6H2 b,a8b,a9
N
N
Ar
N
N
CH3H3C
C6H5OHOHC6H5C6H5
2j + ArCHO
stirring, RT, 5-7 min
H2O
i, ii, iii
(i) H2O, stirring, RT, 5 min (8a,b); ii) H2O/ (SDS), reflux , 1-2 h (8a,b); iii) piperidine / EtOH, US, 5-17 min
(8a,b)
Scheme 3
296 A.A. Al-Mutairi et al.and 60.6–60.7, 162.3, respectively to C-50 and C-60 of the pyran
rings. The protons and carbons in the NMR spectra of 3a–c
were seen at their expected chemical shifts and integral values
(see Section 2). The above NMR spectral data of 3 might cor-
respond to the other tautomeric structure A where the NH
takes position 1 in pyrazole ring (Fig. 1), but the structure of
3 (NH takes position 2) was unambiguously established on
the basis of X-ray crystallographic analysis of 3c (Fig. 2).
Treatment of 2a with 2-(40chlorobenzylidine)malononitrile,
either by stirring overnight or ultrasound for 60 min yielded
the same product 4a (TLC, no depression in the mixed melting
point and the spectral data). Similarly, compound 4b was pre-
pared but ultrasound was applied for 45 min only. IR spectra
of 4a,b showed absorption band at 2201 and 2192 cm1 for ni-
trile groups, and other bands at 3142, 3297, 3183, and 3323 cm
1 corresponding to the amino groups. 1H NMR spectrum of
4a showed a singlet at d 4.62 ppm for H-4, broad singlet at d
7.14 ppm (D2O exchangeable) for the NH2, and two singlets
at d 3.60 and d 1.67 ppm for the protons of the two methylFigure 4 Perspective view ofgroups in positions-1,3, respectively. In the latter spectrum,
the aromatic protons appeared as a pair of doublets at d
7.21 ppm (H-20,60) and d 7.39 ppm (H-30,50) with J= 8.1 Hz.
13C NMR data of 4a,b were in complete agreement with their
structures.
Reaction of the pyrazolones 2e,g with phenylisothiocya-
nate, either by conventional method or by ultrasound, under
the conditions stated in Scheme 2 gave the carbothioamides
5a,b in good-excellent yields. Compound 5a has previously
been prepared by ultrasonic irradiation (Abd EL-Rahman
et al., 2009), and to the best of our knowledge, this is the only
use of this irradiation method in the synthesis of pyrazolone
derivatives. The structures of 5a,b were conﬁrmed by their
spectroscopic data. Thus, IR spectrum of 5b showed absorp-
tion bands at 3145 and 3174 cm1 corresponding to NH/OH
and another band at 1086 and 1087 cm1 due to C‚S stretch-
ing. The mass spectra of both compounds displayed the ex-
pected molecular ions at m/z 309 and 261. 1H NMR
spectrum of 5b exhibited a singlet for N–CH3 at d 3.40 and athe X-ray structure of 8a.
2j + ArCHON
N
H3C
C6H5
O N
N
CH3
C6H5
10a,b
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Ar
 Ar
a    3-OCH3-4-OH-C6H3
b    3,4,5-OCH3C6H2 9a,b
C6H5
 reflux 15 min.
Piperidine/ EtOH
reflux 15 min.
Piperidine/ EtOH
Scheme 4
Microwave versus ultrasound assisted synthesis of some new heterocycles based on pyrazolone moiety 297singlet for D2O exchangeable proton (NH) at d 13.3, in addi-
tion to peaks for the protons of phenyl and ethyl groups in
the structure (see Section 2). The 13C NMR data of 5b
(Fig. 3) were consistent with the proposed structure.
Synthesis of 6c was reported by Da-Ming et al. (1995) via
fusion of 2j with benzil in 74% yield. Treatment of 2j with ben-
zil using either microwave or ultrasound did not yield the de-
sired product and only the starting materials have been
recovered. Therefore, 6a–c have been synthesized by the same
synthetic methodology for 6, and there was no noticeable
improving in the yield. IR of 6a–c displayed two intensive
absorption bands about 1670 and 1690 cm1 due to two
C‚O groups, while their 1H, 13C NMR spectral data were
in good agreement with their structures (see Section 2). The
mass spectra of 6a–c gave molecular ion peaks at m/z 304,
318 and 366, respectively.
Novel 4-arylazo-1,3-disubstituted-1H-pyrazol-5-ols (7a–f)
have been synthesized following the method reported in theFigure 5 Perspective view ofliterature (Zohdi and Rateb, 2003) for 4-p-tolylazo-5-
triﬂuoromethyl-2,4-dihydropyrazol-3-one. The IR spectra of
compounds 7a–f showed absorption bands around 1660 cm1
(C‚O stretch), 1590 cm1 (C‚N stretch) and 1499 cm1
(N‚N stretch). 1H NMR spectra of these compounds revealed
singlet at range d 13.40–13.90 ppm for 5-hydroxyl proton reso-
nance in addition to all protons of all methyl, ethyl and aryl
groups. Furthermore, the 13C NMR spectra conﬁrmed the
structures of these arylazo substituted compounds.
Deb and Bhuyan (2005) reported that stirring a mixture of
equimolar amounts of the pyrazolone 2j and vanilline in water
at room temperature yielded the arylidine derivative 9a. On
repeating the same reaction and applying the same condition
we did not get 9a, but we isolated 8a (Scheme 3). The structure
of 8a was elucidated by spectral data (see Section 2). Fig. 4
shows a perspective view of the structure of 8a, which reveals
that it is actually a 4,40-(4-Hydroxy-3-methoxyphenyl)methyl-
enebis-3-methyl-1-phenyl-1H-pyrazol-5-ol, rather than thethe X-ray structure of 9a.
298 A.A. Al-Mutairi et al.previously reported structure 4-(40-hydroxy-30-methoxybenzyl-
idene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 9a. Com-
pounds 8a,b were also prepared by reﬂuxing a mixture of
equimolar amounts of the pyrazolone 2j and the selected aro-
matic aldehydes in water in the presence of sodium dodecyl
sulfate (SDS). Ultrasound irradiation of a mixture of equimo-
lar amounts of the pyrazolone 2j and the selected aromatic
aldehydes in presence of piperidine yielded 8a,b.
Madkour et al. (2000) reported that reﬂuxing a mixture of
equimolar amounts of pyrazolone 2j and 3,4,5-trimethoxy-
benzaldehyde in absolute ethanol in the presence of catalytic
amount of piperidine afforded the oxinobispyrazole 10b, but
on carrying out the same reaction we did not isolate 10b,
and instead we obtained the arylidine 9b, this means that Kno-
venagel condensation occurred. Similarly, we obtained 9a in-
stead of 10a (Scheme 4). The structures of 9a,b were
elucidated on the basis of spectral analysis. The IR spectrum
of 9a showed absorption bands at 1655 cm1 attributed to con-
jugated C‚O group and absorption bands at 1598 cm1 for
conjugated C‚C. 1H NMR spectra of this compound revealed
singlet at d 7.68 ppm for the oleﬁnic proton beside the CH3
protons and the aromatic ones (see Section 2). 13C NMR data
of 9a were in complete agreement with its structures. Moreover
the mass spectrum of 9a showed the corresponding molecular
ion peaks at m/z= 308. Fig. 5 shows a perspective view of
the structure of 9a, which reveals that it is actually a 4-(40-
hydroxy-30-methoxybenzylidene)-3-methyl-1-phenyl-1H-pyrazol-
5(4H)-one rather than the previously reported structure
oxinobispyrazole.4. Conclusion
Synthesis of some new substituted pyrazolones has been de-
scribed using microwave and ultrasound irradiation methods
as an eco-friendly energy source for the ﬁrst time. Different
reactions have been carried out on some pyrazolones. Struc-
tures of the prepared compounds were elucidated on the basis
of various spectroscopic methods. Additional structural conﬁr-
mation supplied from X-ray crystal structure of three represen-
tative compounds.Acknowledgements
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